De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism
- PMID: 26576547
- PMCID: PMC4765493
- DOI: 10.1007/s10048-015-0466-9
De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism
Abstract
Protein phosphatase 2A (PP2A) is a heterotrimeric protein serine/threonine phosphatase and is involved in a broad range of cellular processes. PPP2R5D is a regulatory B subunit of PP2A and plays an important role in regulating key neuronal and developmental regulation processes such as PI3K/AKT and glycogen synthase kinase 3 beta (GSK3β)-mediated cell growth, chromatin remodeling, and gene transcriptional regulation. Using whole-exome sequencing (WES), we identified four de novo variants in PPP2R5D in a total of seven unrelated individuals with intellectual disability (ID) and other shared clinical characteristics, including autism spectrum disorder, macrocephaly, hypotonia, seizures, and dysmorphic features. Among the four variants, two have been previously reported and two are novel. All four amino acids are highly conserved among the PP2A subunit family, and all change a negatively charged acidic glutamic acid (E) to a positively charged basic lysine (K) and are predicted to disrupt the PP2A subunit binding and impair the dephosphorylation capacity. Our data provides further support for PPP2R5D as a genetic cause of ID.
Keywords: Autism spectrum disorder; De novo mutations; Intellectual disabilities; PPP2R5D; Protein phosphatase; Whole-exome sequencing.
Figures
Similar articles
-
PPP2R5D-Related Intellectual Disability and Neurodevelopmental Delay: A Review of the Current Understanding of the Genetics and Biochemical Basis of the Disorder.Int J Mol Sci. 2020 Feb 14;21(4):1286. doi: 10.3390/ijms21041286. Int J Mol Sci. 2020. PMID: 32074998 Free PMC article. Review.
-
A disorder-related variant (E420K) of a PP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and uncoordinated cell growth.J Biol Chem. 2021 Jan-Jun;296:100313. doi: 10.1016/j.jbc.2021.100313. Epub 2021 Jan 20. J Biol Chem. 2021. PMID: 33482199 Free PMC article.
-
De novo missense variants in PPP1CB are associated with intellectual disability and congenital heart disease.Hum Genet. 2016 Dec;135(12):1399-1409. doi: 10.1007/s00439-016-1731-1. Epub 2016 Sep 28. Hum Genet. 2016. PMID: 27681385 Free PMC article.
-
Disruption of PHF21A causes syndromic intellectual disability with craniofacial anomalies, epilepsy, hypotonia, and neurobehavioral problems including autism.Mol Autism. 2019 Oct 22;10:35. doi: 10.1186/s13229-019-0286-0. eCollection 2019. Mol Autism. 2019. PMID: 31649809 Free PMC article.
-
Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities.Epilepsia. 2014 Apr;55(4):e25-9. doi: 10.1111/epi.12554. Epub 2014 Mar 1. Epilepsia. 2014. PMID: 24579881 Review.
Cited by
-
Co-occurring medical conditions among individuals with ASD-associated disruptive mutations.Child Health Care. 2020;49(4):361-384. doi: 10.1080/02739615.2020.1741361. Epub 2020 Mar 17. Child Health Care. 2020. PMID: 33727758 Free PMC article.
-
Cerebral Palsy Phenotypes in Genetic Epilepsies.Pediatr Neurol. 2024 Aug;157:79-86. doi: 10.1016/j.pediatrneurol.2024.05.016. Epub 2024 May 31. Pediatr Neurol. 2024. PMID: 38901369
-
Hypoglycemia due to PI3K/AKT/mTOR signaling pathway defects: two novel cases and review of the literature.Hormones (Athens). 2021 Dec;20(4):623-640. doi: 10.1007/s42000-021-00287-1. Epub 2021 Apr 20. Hormones (Athens). 2021. PMID: 33876391 Review.
-
PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability.Brain. 2023 Apr 19;146(4):1496-1510. doi: 10.1093/brain/awac326. Brain. 2023. PMID: 36073231 Free PMC article.
-
De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.Am J Hum Genet. 2019 Jan 3;104(1):139-156. doi: 10.1016/j.ajhg.2018.12.002. Epub 2018 Dec 27. Am J Hum Genet. 2019. PMID: 30595372 Free PMC article.
References
-
- Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, van Lier B, Arts P, Wieskamp N, del Rosario M, van Bon BW, Hoischen A, de Vries BB, Brunner HG, Veltman JA. A de novo paradigm for mental retardation. Nature genetics. 2010;42(12):1109–1112. doi:10.1038/ng.712. - PubMed
-
- Ku CS, Polychronakos C, Tan EK, Naidoo N, Pawitan Y, Roukos DH, Mort M, Cooper DN. A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease. Molecular psychiatry. 2013;18(2):141–153. doi:10.1038/mp.2012.58. - PubMed
-
- Depaoli-Roach AA, Park IK, Cerovsky V, Csortos C, Durbin SD, Kuntz MJ, Sitikov A, Tang PM, Verin A, Zolnierowicz S. Serine/threonine protein phosphatases in the control of cell function. Advances in enzyme regulation. 1994;34:199–224. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
